Pattern Bioscience, a leader in rapid diagnostic technologies for bacterial infections, has announced it has raised US$43 million in Series D financing. The round was led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funding will support the completion of a US multi-center clinical trial and regulatory submission for the Pneumonia ID/AST Panel, designed to diagnose critically ill patients with suspected pneumonia. The panel has been granted Breakthrough Device Designation by the FDA and is supported by a BARDA contract valued at up to US$40.9 million.
Latham & Watkins LLP represented Pattern Bioscience in the transaction with a team led by Austin/Houston partner Scott Craig, with associates Kristine LaVeau, Luisa Gomez, and Regan Barney.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
